Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3'-uridinemonophosphate
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
3'-Uridinemonophosphate (3'-UMP) is an experimental small molecule compound and a ribonucleoside 3'-phosphate. It is a structural isomer of the more common 5'-uridinemonophosphate, characterized by a phosphate group esterified to the C-3' position of the ribose sugar. While it occurs naturally as a product of RNA degradation by certain ribonucleases, it has no approved therapeutic uses and is not currently associated with any clinical trials or pharmaceutical development programs. It is primarily utilized as a biochemical research reagent and a reference standard in analytical chemistry.
- Other names
- 3'-Uridylic aciduridine 3'-monophosphate3'-UMP
Beyond the preview
Go deeper on 3'-uridinemonophosphate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 3'-uridinemonophosphate.